> ## Content Index
> Fetch the complete content index at: https://aiadoption.org/llms.txt
> Use this file to discover other available public pages before exploring further.

# AI-driven protein research grew 71% in one year
- URL: https://aiadoption.org/ai-analysis/ai-driven-protein-research-grew-71-in-one-year/
- Published: 2026-08-02T08:36:08.000Z
- Updated: 2026-08-02T08:36:08.000Z
- Description: AI-driven protein research grew approximately 71% between 2024 and 2025 — from 2,259 to 3,855 publications across four categories. Protein-drug interactions led at 54.4% of papers in 2025. AI for drug discovery publications have followed a similar steep upward trajectory, reaching 3,311 in 2025.
- Author: Manu
- Tags: AI Analysis, AI in Healthcare, AI Research, AI Economics

If your strategic view of where AI is producing visible scientific output treats the major application domains (language, vision, code, robotics) as the primary spaces and biological research as a slower-moving secondary application, the 2024-2025 publication data shows biological AI is moving at one of the fastest research rates of any AI application area. AI-driven protein research publications grew approximately 71% between 2024 and 2025, from 2,259 to 3,855 papers across four categories. AI for drug discovery publications followed a similar steep trajectory, reaching 3,311 in 2025 from 431 in 2018\. Multimodal biomedical AI publications grew from 2 in 2021 to 462 in 2025\. The category is a structural research priority for the global AI community, not a peripheral application area.

*AI-driven protein research publications by category, 2024 vs 2025:* 

The protein research category breakdown shows the within-category dynamics. Across four research areas:

- **Protein-drug interactions**: 1,127 papers in 2024 → 2,097 in 2025 (+86%). Largest category, fastest absolute growth. Reflects rising therapeutic applications.
- **Protein structure prediction**: 648 → 922 (+42%). Share declined from 28.7% of the total to 23.9% as the field matures and cofolding methods become standard.
- **Synthetic protein design**: 264 → 434 (+64%). Reflects emergence of generative protein design (RFDiffusion, BoltzGen, BindCraft, Germinal, Mosaic).
- **Function prediction**: 220 → 402 (+83%). Reflects continued interest in mapping protein sequence to function.

> The data observation: every category grew substantially. The 71% aggregate growth understates the variation: protein-drug interactions and function prediction grew faster than the aggregate, while structure prediction grew slower as the field matures.

Publications on AI for drug discovery, 2018–25: 

The 2018-2025 compound annual growth rate is approximately 33%, sustained over seven years. The 2025 single-year growth (2,100 → 3,311) is approximately 58%, accelerating from earlier years.

### Three structural drivers explain the trajectory.

**The first driver:** foundation models opened the methodological frontier. AlphaFold 2 (2021) made high-accuracy protein structure prediction widely accessible. AlphaFold 3 (2024) extended this to cofolding (protein-protein, protein-nucleic acid, protein-drug complexes). The Boltz series and OpenFold3 (2025) made similar capability available under commercially permissive licences. Each release expanded what researchers could investigate computationally, driving research output.

**The second driver:** therapeutic relevance creates funding pressure. Protein-drug interactions, drug discovery, and synthetic protein design all map directly to pharmaceutical industry priorities. The funding environment for biological AI research has substantial commercial backing. Insitro, Recursion, Schrödinger, Atomwise, Isomorphic Labs (DeepMind's drug discovery subsidiary), and many smaller firms all fund research output and acquire research talent. The commercial pull translates to higher research productivity.

**The third driver:** dataset infrastructure matured. Biological AI models are increasingly bottlenecked on data rather than architecture. But "bottlenecked on data" does not mean "no data": it means data quality, integration, and curation are the limiting factors. The 2025 dataset releases (Tahoe-100M, BaseData, distilled datasets from AlphaFold predictions) substantially expanded the training data available for biological AI research. Models trained on better data produce stronger results, which drives more research output building on those results.

> **The data observation:** AI-driven biological research is one of the fastest-growing research domains in 2024-2025\. The trajectory shows no signs of slowing.

### The trajectory implications are substantial for organisations and researchers operating in adjacent spaces.

**The first implication:** biological AI is competing with general AI for research talent. Researchers who could work on either domain are increasingly choosing biological AI because of the visible research output, commercial backing, and direct human-benefit applications. The talent flow has implications for general AI research capacity if biological AI continues to outpace general AI in attractiveness.

**The second implication:** pharmaceutical industry strategy depends on engaging with the research output. The 71% protein research growth, the 58% drug discovery growth, and the comparable rates in adjacent areas mean the pharmaceutical industry's competitive landscape is shifting rapidly. Firms that engage with the current research output (through internal capability, partnerships with AI-first biotech, or M&A) will adapt. Firms that wait for the dust to settle will face structural disadvantage.

**The third implication:** research infrastructure investment matters for national competitiveness. The countries and research organisations producing the highest volume and quality of biological AI research will shape the next generation of pharmaceutical and biotechnology industries. National investment in biological AI research infrastructure (compute, data, talent, regulatory frameworks for AI in clinical trials) has long-term economic consequences.

**The fourth implication:** the multidisciplinary nature of biological AI requires sustained investment in cross-disciplinary capability. The 462 multimodal biomedical AI publications in 2025 reflect research that combines biological data (proteins, cells, tissues) with imaging, text, and other modalities. The capability requires expertise across multiple domains. Organisations that build these cross-disciplinary teams (combining biology, chemistry, machine learning, clinical medicine, and data engineering) will produce research that organisations with single-discipline teams cannot match.

### The trajectory observation has practical strategic implications for 2026 planning.

For organisations setting biomedical AI strategy in 2026, the trajectory anchor is that AI in biology is one of the fastest-growing research domains globally, producing structural shifts in pharmaceutical industry, biotech investment, and basic biological research over the next 24-36 months. Strategic plans that engage with this trajectory at scale (with substantial investment in research capability, partnerships, and infrastructure) will be positioned competitively. Plans that treat biological AI as a peripheral application area will face widening competitive gaps as the trajectory continues.

For organisations setting general AI strategy in 2026, the biological AI trajectory is a leading indicator for what AI capability development looks like in domains with substantial commercial backing, strong dataset infrastructure, and methodological foundation models that enable broad research community participation. The same dynamics may apply to other application domains (climate, materials, finance) as they develop similar infrastructure.

> The trajectory: through 2026-2028, biological AI research output is likely to continue compounding at 30-60% annual growth rates. The cumulative effect over 2024-2030 will produce a research base substantially larger than the cumulative output through 2024\. The pharmaceutical and biotechnology industries that operate on this research base will look structurally different by 2030 than they look today.

**The data is clear:** AI-driven biological research is one of the most consequential AI application areas in the 2024-2030 horizon. Strategic positioning decisions made in 2026 will shape competitive outcomes for the next decade.